BioRestorative Therapies Announces CRO Agreement with PRC Clinical for its BRTX-100 Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
21 déc. 2021 16h01 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Dec. 21, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based...
BioRestorative Therapies CEO Interviewing Live on the James Hicks NewMedia Show
21 déc. 2021 06h00 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Dec. 21, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based...
BioRestorative Therapies, Inc. Releases Year-End Message
20 déc. 2021 06h00 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based...
BioRestorative Therapies Announces Filing of Ten Patent Applications Related to its BRTX-100 Program
02 déc. 2021 06h00 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Dec. 02, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based...
BioRestorative Therapies Enters into Letter of Intent with PRC Clinical
19 nov. 2021 06h00 HE
|
BioRestorative Therapies, Inc
PRC Clinical to Provide Start-up CRO Services for BRTX-100 Phase 2 Clinical Trial MELVILLE, N.Y., Nov. 19, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or...
BioRestorative Therapies Appoints Robert Kristal as Chief Financial Officer
10 nov. 2021 06h00 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced...
BioRestorative Therapies Announces Closing of $23 Million Public Offering
09 nov. 2021 14h20 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced...
BioRestorative Therapies Prices $23 Million Public Offering and Uplisting to the Nasdaq Capital Market
04 nov. 2021 21h21 HE
|
BioRestorative Therapies, Inc
Common stock will begin trading on The Nasdaq Capital Market under the ticker symbol “BRTX” November 5, 2021 MELVILLE, N.Y., Nov. 04, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc....
BioRestorative Therapies Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq
26 oct. 2021 16h05 HE
|
BioRestorative Therapies, Inc
MELVILLE, NY, Oct. 26, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BRTX” or the “Company”) (OTC: BRTX), a life sciences company focused on adult stem cell-based therapies, today...
BioRestorative Therapies Announces Nomination of Two New Members to the Board of Directors
26 oct. 2021 08h00 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today...